Efficacy of osimertinib in the treatment of EGFR mutation-positive NSCLC complicated with malignant pleural effusion

Objective To investigate the efficacy of osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), in the treatment of EGFR mutation-positive (EGFR m+) non-small cell lung cancer (NSCLC) complicated with malignant pleural effusion (MPE). Methods Retrosp...

Descrizione completa

Dettagli Bibliografici

Autori principali:	RONG Tianming, ZHU Ziwen, XIANG Rongrong, DU Zehua, WANG Hongbing
Natura:	Artigo
Lingua:	Chinês
Pubblicazione:	Editorial Office of Journal of Xuzhou Medical University 2026-02-01
Serie:	徐州医科大学学报
Soggetti:	osimertinib non-small cell lung cancer gene mutation malignant pleural effusion pleural perfusion
Accesso online:	https://xb.xzhmu.edu.cn/article/doi/10.12467/j.issn.2096-3882.20250673
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!